About VenBio
VenBio is a venture capital firm founded in 2011. It is primarily based out of San Francisco, United States. As of Jun 2026, VenBio is an active investor, having invested in 62 companies, with 3 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series A round of Oak Bio Co Overall, VenBio portfolio has seen 21 IPOs and 17 acquisitions including key companies like Apellis Pharmaceuticals, Harmony Biosciences and Ventyx Biosciences. A lot of funds co-invest with VenBio, with names like Vivo Capital sharing a substantial percentage of its portfolio. VenBio has team of 7 people including 4 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 5 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
VenBio's List of Top Investments
VenBio has a portfolio of 62 companies. Their most notable investments are in Aeovian Pharmaceuticals and Entact Bio.Their portfolio spans across United States, Canada, Netherlands and 4 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 3 other sectors, across stages such as Series A, Series B and 5 more. Here is the list of top investments by VenBio:Developer of therapeutics for the treatment of rare diseases. The company is developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. The company develops programs across ophthalmology, nephrology, hematology, and neurology.
Key facts about Apellis Pharmaceuticals
- Founded Year: 2008
- Location: Crestwood (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $213M
- Employee Count: 639 as on May 31, 2026
- Investors: Avoro Capital, VenBio and 21 Others
- Latest Funding Round: Post IPO, May 07, 2020, $*****
- Highlight: Acquired
Developer of therapeutics for rare neurological diseases. The company is engaged in the research, development, and commercialization of novel treatments for rare diseases mainly CNS disorders including Wakix for Narcolepsy.
Key facts about Harmony Biosciences
- Founded Year: 2017
- Location: Plymouth Meeting (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $345M
- Employee Count: 344 as on Jun 30, 2026
- Investors: Fidelity Investments, VenBio and 12 Others
- Latest Funding Round: Conventional Debt, Jan 27, 2020, $*****
- Highlight: Public
Developer of therapeutics to treat autoimmune diseases. The company's pipeline drugs include VTX958 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002 S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735 peripheral inhibitor of the NLRP3 inflammasome. These drugs are used for the treatment of autoimmune disorders by regulating the innate and adaptive immunity to activate type 1 interferon, IL-12, and IL-23 signaling.
Key facts about Ventyx Biosciences
- Founded Year: 2018
- Location: Encinitas (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $165M
- Employee Count: 237 as on Jun 30, 2026
- Investors: RTW Investments, Third Point and 13 Others
- Latest Funding Round: Post IPO, Sep 23, 2024, $*****
- Highlight: Acquired
Developer of therapeutics for autoimmune diseases. Its lead candidate voclosporin was developed for the treatment of lupus nephritis (LN). Other candidates includes AUR200 is a highly potent and specific immune modulator of BAFF and APRIL activity and AUR300 is a novel peptide therapeutic for autoimmune and fibrotic diseases.
Key facts about Aurinia Pharmaceuticals
- Founded Year: 1993
- Location: Edmonton (Canada)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Employee Count: 156 as on Jun 30, 2026
- Investors: VenBio, RA Capital Management and 10 Others
- Latest Funding Round: Post IPO, Dec 28, 2016, $*****
- Highlight: Public
5. Alumis
Developer of therapeutics for the treatment of auto-immune disease. The lead candidate SK-001 is a potentially best-in-class TYK2 inhibitor for psoriasis treatment. The TYK2 is a gene that encodes a member of the tyrosine kinase which is a key mediator of inflammation and autoimmune diseases.
Key facts about Alumis
- Founded Year: 2003
- Location: San Francisco (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $529M
- Employee Count: 251 as on Jun 30, 2026
- Investors: Foresite Capital, Nextech Invest and 15 Others
- Latest Funding Round: Post IPO, Jul 17, 2024, $*****
- Highlight: Public
VenBio's Year-on-Year Investment Trends
VenBio has invested in 62 companies over the last 14 years, with an average of 4 new investments annually in the last 10 years. In 2025, it made 3 investments, while as of Jun 2026, it has made 4 investments in this year. Its most recent first time investment was in Oak Bio Co and most recent follow-on round was in Parabilis Medicines.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 3 | 1 | 4 |
2025 | 1 | 2 | 3 |
2024 | 5 | 1 | 6 |
2023 | 2 | 1 | 3 |
2022 | 4 | 2 | 6 |
2021 | 6 | 7 | 13 |
2020 | 9 | 3 | 12 |
2019 | 4 | 1 | 5 |
2018 | 4 | 4 | 8 |
2017 | 4 | 3 | 7 |
VenBio's Investments by Stage
VenBio has made 26 investments in Series A stage with an average round size of $49M, 12 investments in Series B stage with an average round size of $107M and 7 investments in Series D stage with an average round size of $179M.Stage of entry | No. of Investments |
|---|---|
Series A | 26 |
Series B | 12 |
Series C | 7 |
Series D | 7 |
Post IPO | 4 |
Others | 2 |
Note: We have considered here, only first round of investments
VenBio's Investments by Sector
VenBio has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Healthcare. Notably, it has invested in 55 Tech companies, 51 Enterprise (B2B) companies, 6 Software companies and at least 2 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 52 |
High Tech | 4 |
Enterprise Applications | 3 |
HealthTech | 3 |
Healthcare | 3 |
Others | 2 |
Note: We have considered here, only first round of investments
VenBio's Investments by Geography
VenBio has made most investments in United States (48), followed by Canada where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 48 |
Canada | 3 |
Netherlands | 2 |
United Kingdom | 2 |
Australia | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
VenBio's recent investments
VenBio has made 4 investments in 2026 so far. Oak Bio Co and Oak Hill Bio are the latest among them.Here are the most recent investments by VenBio:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 03, 2026 | United Kingdom | Series A | 3456 | ||
Jun 02, 2026 | Canada | Series A | 5678 | ||
Apr 21, 2026 | United States | Post IPO | 1226 | ||
Jan 08, 2026 | United States | Series F | 4449 | [+18] | |
Nov 18, 2025 | United States | Series B | 2821 | [+8] |
IPOs and Publicly Listed companies in VenBio's Portfolio
21 of VenBio's portfolio companies have become public. Attovia got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2026 at marketcap of $731M and Parabilis Medicines got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $2.33B.Here are VenBio's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 05, 2026 | May 09, 2024 | Series B | 1482 | |
Jun 10, 2026 | Nov 17, 2022 | Series D | 7559 | |
Jul 19, 2024 | Jun 26, 2020 | Series A | 5678 | |
Jun 28, 2024 | Mar 07, 2024 | Series C | 5219 | |
May 05, 2023 | Nov 16, 2021 | Series B | 8688 |
Acquired companies in VenBio's Portfolio
17 companies from VenBio's portfolio have been acquired. The most recent acquisition was Candid Therapeutics in May 2026 by UCB for $*****.Here are VenBio's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 03, 2026 | Sep 09, 2024 | Series D | 4372 | |
Mar 31, 2026 | Jan 29, 2016 | Series D | 5578 | |
Jan 07, 2026 | Mar 09, 2021 | Series B | 6064 | |
Oct 09, 2025 | Jun 22, 2018 | Series A | 9395 | |
Jul 22, 2025 | Sep 23, 2024 | Series B | 2398 |
Team profile of VenBio
VenBio has a team of 7 members including 4 Partners and 1 Principal located in United States. VenBio's team sits on the board of 1 company.Here is a list of all team members in VenBio:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Partner | Seattle | - | - | |
Partner | - | |||
Partner | San Francisco | - | ||
Principal | San Francisco | - |
Co-investors of VenBio
Over the past 14 years, 361 investors have co-invested in VenBio's portfolio companies. This includes funds and angels.
- Invested before VenBio: HHS, Orbimed and 86 others have invested in rounds before VenBio. There are 6 companies where HHS has invested before VenBio and 4 companies where Orbimed has invested before VenBio.
- Top Co-investors of VenBio: 161 investors entered a company along with VenBio. These include investors like Vivo Capital (11 companies).
- Invested after VenBio: A total of 112 investors have invested in VenBio's portfolio after their investments. Top Investors include Vivo Capital (6 companies), Janus Henderson Investors (6 companies) and RA Capital Management (4 companies).
Recent News related to VenBio
•
•
•
Parabilis gets $305M to conquer 'undruggable' proteins after early successEndpoints•Jan 08, 2026•Parabilis Medicines, Johnson & Johnson, Frazier Life Sciences, Rock Springs Capital and 19 others
•
Aeovian gets $55M for tuberous sclerosis complex, to explore prospects in obesityEndpoints•Dec 16, 2025•Aeovian Pharmaceuticals, Hevolution, Sofinnova Investments, CTI Life Sciences Fund and 7 others
•
Lexeo Therapeutics Partners with PXV Funds and venBio for Cardiac RNA TherapeuticsGlobeNewswire•Jun 24, 2025•LEXEO Therapeutics, Xontogeny, VenBio
•
Axonis snags $115M to test oral drugs for epilepsy and neuropathic painEndPoints News•Oct 30, 2024•AXONIS Therapeutics, Cormorant Asset Management, VenBio, Sofinnova Investments and 6 others
•
Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent VaccinePR Newswire•Sep 23, 2024•Vicebio, TCG Crossover, Avoro Capital, VenBio and 6 others
•
T-cell targeting Candid Therapeutics launches with $370mPharmaceutical Technology•Sep 10, 2024•Candid Therapeutics, Venrock, VenBio, Foresite Capital and 3 others
•
Candid Therapeutics Debuts With $370m Capital Raise To Clinically Evaluate Potentially Transformative Autoimmune TherapiesBusiness Wire•Sep 09, 2024•Candid, Venrock, Fairmont, TCG Crossover and 16 others
•
Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune TherapiesThe Joplin Globe•Sep 09, 2024•Candid Therapeutics, Third Rock Ventures, Orbimed, Foresite Capital and 5 others
